HANGZHOU, China and SAN FRANCISCO, Aug. 9, 2022– Sciwind Biosciences Co Ltd, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced positive interim topline results from a 26-week Phase 1c/2a clinical trial of XW003 (Ecnoglutide) in overweight or obese Chinese adult